Omentin changes following bariatric surgery and predictive links with biomarkers for risk of cardiovascular disease

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Lapointe, Marc ^a   Poirier, Paul ^a,b   Martin, Julie ^a,b   Bastien, Marjorie ^a,b   Auclair, Audrey ^a,b   Cianflone, Katherine ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

NT proBNP; Obesity; Weight loss

Indexed keywords

ADIPOCYTOKINE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BILIRUBIN; BIOLOGICAL MARKER; HOMOCYSTEINE; INSULIN; OMENTIN; UNCLASSIFIED DRUG; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

ADULT; AGE; ARTICLE; BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; BILIRUBIN BLOOD LEVEL; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETES MELLITUS; ERYTHROCYTE COUNT; FAT MASS; FEMALE; HUMAN; IMMUNOLOGICAL PARAMETERS; INSULIN SENSITIVITY; LEUKOCYTE COUNT; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUTROPHIL; POSTOPERATIVE PERIOD; SEX RATIO; WAIST CIRCUMFERENCE; ADVERSE EFFECTS; BLOOD; CARDIOVASCULAR DISEASES; MIDDLE AGED; OBESITY; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE; RISK FACTOR; TRENDS;

ADULT; BARIATRIC SURGERY; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CYTOKINES; FEMALE; GPI-LINKED PROTEINS; HUMANS; LECTINS; MALE; MIDDLE AGED; OBESITY; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 84906837447     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-014-0124-9     Document Type: Article

References (38)

1. Jaikanth C, Gurumurthy P, Cherian KM, Indhumathi T. Emergence of omentin as a pleiotropic adipocytokine. Exp Clin Endocrinol Diabetes 2013, 121:377-383. 10.1055/s-0033-1345123, 23839538.
2. Scha¨ffler A, Neumeier M, Herfarth H, Fu¨rst A, Scho¨lmerich J, Bu¨chler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005, 1732:96-102. 10.1016/j.bbaexp.2005.11.005, 16386808.
3. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, 290:E1253-E1261. 10.1152/ajpendo.00572.2004, 16531507.
4. Kazama K, Usui T, Okada M, Hara Y, Yamawaki H. Omentin plays an anti-inflammatory role through inhibition of TNF-?-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol 2012, 686:116-123. 10.1016/j.ejphar.2012.04.033, 22554771.
5. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56:1655-1661. 10.2337/db06-1506, 17329619.
6. Shibata R, Ouchi N, Takahashi R, Terakura Y, Ohashi K, Ikeda N, Higuchi A, Terasaki H, Kihara S, Murohara T. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr 2012, 4:37. 10.1186/1758-5996-4-37, 22835063.
7. Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer AA. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab 2013, 98:E514-E517. 10.1210/jc.2012-3673, 23303213.
8. Liu R, Wang X, Bu P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract 2011, 93:21-25. 10.1016/j.diabres.2011.03.001, 21497934.
9. Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, Ohashi K, Ikeda N, Kihara S, Murohara T. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 2011, 219:811-814. 10.1016/j.atherosclerosis.2011.08.017, 21925659.
10. Yoo HJ, Hwang SY, Hong HC, Choi HY, Yang SJ, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS, Baik SH. Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes. Cardiovasc Diabetol 2011, 10:103. 10.1186/1475-2840-10-103, 22108456.
11. Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010, 88:29-33. 10.1016/j.diabres.2010.01.013, 20129687.
12. El-Mesallamy HO, El-Derany MO, Hamdy NM. Serum omentin-1 and chemerin levels are interrelated in patients with Type 2 diabetes mellitus with or without ischaemic heart disease. Diabet Med 2011, 28:1194-1200. 10.1111/j.1464-5491.2011.03353.x, 21668495.
13. Moreno-Navarrete JM, Catala´n V, Ortega F, Go´mez-Ambrosi J, Ricart W, Fru¨hbeck G: Ferna´ndez-Real JM. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 2010, 7:27. 10.1186/1743-7075-7-27.
14. Saremi A, Asghari M, Ghorbani A. Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. J Sports Sci 2010, 28:993-998. 10.1080/02640414.2010.484070, 20544489.
15. Tan BK, Adya R, Farhatullah S, Lewandowski KC, O'Hare P, Lehnert H, Randeva HS. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008, 57:801-808. 10.2337/db07-0990, 18174521.
16. Poirier P, Cornier MA, Mazzone T, Stiles S, Cummings S, Klein S, McCullough PA, Ren Fielding C, Franklin BA. American heart association obesity committee of the council on nutrition, physical activity, and metabolism. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation 2011, 123:1683-1701. 10.1161/CIR.0b013e3182149099, 21403092.
17. Brethauer SA, Aminian A, Romero-Talama´s H, Batayyah E, Mackey J, Kennedy L, Kashyap SR, Kirwan JP, Rogula T, Kroh M, Chand B, Schauer PR. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg 2013, 258:628-636. 24018646.
18. Sjo¨stro¨m L, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden T, Bouchard C, Carlsson B, Karason K, Lo¨nroth H, Na¨slund I, Sjo¨stro¨m E, Taube M, Wedel H, Svensson PA, Sjo¨holm K, Carlsson LM. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014, 311:2297-2304. 10.1001/jama.2014.5988, 24915261.
19. Habib P, Scrocco JD, Terek M, Vanek V, Mikolich JR. Effects of bariatric surgery on inflammatory, functional and structural markers of coronary atherosclerosis. Am J Cardiol 2009, 104:1251-1255. 10.1016/j.amjcard.2009.06.042, 19840571.
20. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292:1724-1737. 10.1001/jama.292.14.1724, 15479938.
21. Munkonda MN, Martin J, Poirier P, Carrington A, Biron S, Lebel S, Cianflone K. Acylation stimulating protein reduction precedes insulin sensitization after BPD-DS bariatric surgery in severely obese women. Nutr Diabetes 2012, 2:e41. 10.1038/nutd.2012.13, 23448805.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502. 4337382.
23. Hanusch-Enserer U, Hermann KM, Cauza E, Spak M, Ma¨hr B, Dunky A, Rosen HR, Ko¨ller U, Prager R. Effect of gastric banding on aminoterminal pro-brain natriuretic peptide in the morbidly obese. Obes Res 2003, 11:695-698. 10.1038/oby.2003.99, 12805390.
24. Go¨rmu¨s U, Ozmen D, Ozmen B, Parildar Z, Ozdogan O, Mutaf I, Bayindir O. Serum N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) and homocysteine levels in type 2 diabetic patients with asymptomatic left ventricular diastolic dysfunction. Diabetes Res Clin Pract 2010, 87:51-56. 10.1016/j.diabres.2009.10.010, 19932518.
25. MacGowan GA, Neely D, Peaston R, Wrightson N, Parry G. Evaluation of NT-proBNP to predict outcomes in advanced heart failure. Int J Clin Pract 2010, 64:892-899. 10.1111/j.1742-1241.2010.02388.x, 20584222.
26. Ahluwalia N, Blacher J, Szabo de Edelenyi F, Faure P, Julia C, Hercberg S, Galan P. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis 2013, 228:478-484. 10.1016/j.atherosclerosis.2013.03.017, 23582589.
27. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Clin Proc 2008, 83:1203-1212. 10.4065/83.11.1203.
28. Cho HC. The relationship among homocysteine, bilirubin, and diabetic retinopathy. Diab Metab J 2011, 35:595-601. 10.4093/dmj.2011.35.6.595.
29. Tzotzas T, Evangelou P, Kiortsis DN. Obesity, weight loss and conditional cardiovascular risk factors. Obes Rev 2011, 12:e282-e289. 10.1111/j.1467-789X.2010.00807.x, 21054756.
30. Biegus J, Zymlinski R, Sokolski M, Nawrocka S, Siwolowski P, Szachniewicz J, Jankowska EA, Banasiak W, Ponikowski P. Liver function tests in patients with acute heart failure. Pol Arch Med Wewn 2012, 122:471-479. 23037318.
31. Onat A, Can G, O¨rnek E, C¸ic¸ek G, Ayhan E, Dogan Y. Serum Y-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease. Obesity (Silver Spring) 2012, 20:842-848. 10.1038/oby.2011.136.
32. Giral P, Ratziu V, Couvert P, Carrie´ A, Kontush A, Girerd X, Chapman MJ. Plasma bilirubin and gamma-glutamyltransferase activity are inversely related in dyslipidemic patients with metabolic syndrome: relevance to oxidative stress. Atherosclerosis 2010, 210:607-613. 10.1016/j.atherosclerosis.2009.12.026, 20129611.
33. Narumi T, Watanabe T, Kadowaki S, Kinoshita D, Yokoyama M, Honda Y, Otaki Y, Nishiyama S, Takahashi H, Arimoto T, Shishido T, Miyamoto T, Kubota I. Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure. Cardiovasc Diabetol 2014, 13:84. 10.1186/1475-2840-13-84, 24755035.
34. Kataoka Y, Shibata R, Ohashi K, Kambara T, Enomoto T, Uemura Y, Ogura Y, Yuasa D, Matsuo K, Nagata T, Oba T, Yasukawa H, Numaguchi Y, Sone T, Murohara T, Ouchi N. Omentin prevents myocardial ischemic injury through AMPK- and Akt-dependent mechanisms. J Am Coll Cardiol 2014, 63:2722-33. 10.1016/j.jacc.2014.03.032, 24768874.
35. Tsuji S, Uehori J, Matsumoto M, Suzuki Y, Matsuhisa A, Toyoshima K, Seya T. Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem 2001, 276:23456-23463. 10.1074/jbc.M103162200, 11313366.
36. Caricilli AM, Saad MJ. Gut microbiota composition and its effects on obesity and insulin resistance. Curr Opin Clin Nutr Metab Care 2014, 17:312-318. 10.1097/MCO.0000000000000067, 24848531.
37. Erejuwa OO, Sulaiman SA, Ab Wahab MS. Modulation of gut microbiota in the management of metabolic disorders: the prospects and challenges. Int J Mol Sci 2014, 15:4158-4188. 10.3390/ijms15034158, 24608927.
38. Onat A, Can G. Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des 2014, 20:575-584. 10.2174/138161282004140213145551, 23565630.